)
)
)
SpliSense
SpliSense is a clinical-stage biotech developing inhaled RNA-based antisense oligonucleotide (ASO) therapies for severe pulmonary diseases, including cystic fibrosis, COPD, asthma, non-CF bronchiectasis, and IPF. With positive Phase 2 efficacy data in CF and two additional programs entering the clinic by 2026, SpliSense’s platform offers a novel, promising approach to treating respiratory diseases.
Address
JerusalemIsrael
Israel
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)